Literature DB >> 19537779

Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.

Jennifer N Rees1, Virginia R Florang, Laurie L Eckert, Jonathan A Doorn.   

Abstract

Dopamine (DA) has been implicated as an endogenous neurotoxin to explain selective neurodegeneration, as observed for Parkinson's disease (PD). However, previous work demonstrated that 3,4-dihydroxyphenylacetaldehyde (DOPAL) was more toxic than DA. DOPAL is generated as a part of DA catabolism via the activity of monoamine oxidase, and the mechanism of DOPAL toxicity is proposed to involve protein modification. Previous studies have demonstrated protein reactivity via the aldehyde moiety; however, DOPAL contains two reactive functional groups (catechol and aldehyde), both with the potential for protein adduction. The goal of this work was to determine whether protein modification by DOPAL occurs via a thiol-reactive quinone generated from oxidation of the catechol, which is known to occur for DA, or if the aldehyde forms adducts with amine nucleophiles. To accomplish this objective, the reactivity of DOPAL toward N-acetyl-lysine (NAL), N-acetyl-cysteine (NAC), and two model proteins was determined. In addition, several DOPAL analogues were obtained and used for comparison of reactivity. Results demonstrate that at pH 7.4 and 37 degrees C, the order of DOPAL reactivity is NAL >> NAC and the product of NAL and DOPAL is stable in the absence of reducing agent. Moreover, DOPAL will react with model proteins, but in the presence of amine-selective modifiers citraconic anhydride and 2-iminothiolane hydrochloride, the reactivity of DOPAL toward the proteins is diminished. In addition, DOPAL-mediated protein cross-linking is observed when a model protein or a protein mixture (i.e., mitochondria lysate) is treated with DOPAL at concentrations of 5-100 microM. Protein cross-linking was diminished in the presence of ascorbate, suggesting the involvement of a quinone in DOPAL-mediated protein modification. These data indicate that DOPAL is highly reactive toward protein nucleophiles with the potential for protein cross-linking.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19537779      PMCID: PMC2717024          DOI: 10.1021/tx9000557

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  38 in total

1.  Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.

Authors:  William J Burke; Vijaya B Kumar; Neeraj Pandey; W Michael Panneton; Qi Gan; Mark W Franko; Mark O'Dell; Shu Wen Li; Yi Pan; Hyung D Chung; James E Galvin
Journal:  Acta Neuropathol       Date:  2007-10-27       Impact factor: 17.088

Review 2.  Altered vesicular dopamine storage in Parkinson's disease: a premature demise.

Authors:  W Michael Caudle; Rebecca E Colebrooke; Piers C Emson; Gary W Miller
Journal:  Trends Neurosci       Date:  2008-05-09       Impact factor: 13.837

3.  Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography.

Authors:  W J Burke; H D Chung; S W Li
Journal:  Anal Biochem       Date:  1999-08-15       Impact factor: 3.365

4.  Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease.

Authors:  T G Hastings; D A Lewis; M J Zigmond
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

Review 5.  Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase.

Authors:  Satori A Marchitti; Richard A Deitrich; Vasilis Vasiliou
Journal:  Pharmacol Rev       Date:  2007-03-22       Impact factor: 25.468

6.  Reactions of biogenic aldehydes with hemoglobin.

Authors:  A Helander; O Tottmar
Journal:  Alcohol       Date:  1989 Jan-Feb       Impact factor: 2.405

7.  3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.

Authors:  S W Li; T S Lin; S Minteer; W J Burke
Journal:  Brain Res Mol Brain Res       Date:  2001-09-10

8.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

9.  Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease.

Authors:  M B Mattammal; R Strong; V M Lakshmi; H D Chung; A H Stephenson
Journal:  J Neurochem       Date:  1995-04       Impact factor: 5.372

Review 10.  3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.

Authors:  W J Burke
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2003-04
View more
  61 in total

1.  Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.

Authors:  Lydia M Mexas; Virginia R Florang; Jonathan A Doorn
Journal:  Neurotoxicology       Date:  2011-04-14       Impact factor: 4.294

Review 2.  Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.

Authors:  David S Goldstein
Journal:  Cell Mol Neurobiol       Date:  2012-07       Impact factor: 5.046

3.  Catechols in post-mortem brain of patients with Parkinson disease.

Authors:  D S Goldstein; P Sullivan; C Holmes; I J Kopin; M J Basile; D C Mash
Journal:  Eur J Neurol       Date:  2010-11-12       Impact factor: 6.089

4.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

Review 5.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

6.  Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).

Authors:  Cristian Follmer; Eduardo Coelho-Cerqueira; Danilo Y Yatabe-Franco; Gabriel D T Araujo; Anderson S Pinheiro; Gilberto B Domont; David Eliezer
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

7.  Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.

Authors:  Jonathan W Werner-Allen; Sarah Monti; Jenna F DuMond; Rodney L Levine; Ad Bax
Journal:  Biochemistry       Date:  2018-02-15       Impact factor: 3.162

Review 8.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

9.  Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts.

Authors:  Nina Kaludercic; Andrea Carpi; Takahiro Nagayama; Vidhya Sivakumaran; Guangshuo Zhu; Edwin W Lai; Djahida Bedja; Agnese De Mario; Kevin Chen; Kathleen L Gabrielson; Merry L Lindsey; Karel Pacak; Eiki Takimoto; Jean C Shih; David A Kass; Fabio Di Lisa; Nazareno Paolocci
Journal:  Antioxid Redox Signal       Date:  2013-05-22       Impact factor: 8.401

10.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Rachel Sullivan; Daniel J Gross; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2012-10-25       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.